Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly.See plans and pricing.See plans →
Convergen secures $15 million Seed+ financing led by MPCi to advance therapeutics for protein aggregation diseases.
PRIVATEAug 31, 2026•7 days ago
Amount Raised
$15 Million
Round Type
Seed
Suzhou CityBiotechnologyHealth CareMedical
Investors
Bio Track CapitalLavMp Ci
Description
Convergen, a biotechnology company, announced the closing of a $15 million Seed+ financing round. The funds will be used to advance Convergen's proprietary degrader platform and accelerate its pipeline for neurodegenerative disorders. This round includes participation from LAV, BioTrack Capital, and a leading biotech fund. Convergen aims to bring new therapeutic options to patients with neurodegenerative diseases and other conditions driven by pathological protein aggregates.
Company Information
Company
Convergen
Location
Suzhou City, Jiangsu, China
About
Convergen is a biotech company pioneering TrimTAC—next-generation bifunctional degraders that leverage TRIM21 to selectively clear pathological multimeric proteins. Founded to address unmet medical needs in neurodegenerative disease and beyond, the company combines cutting-edge academic research with industry-proven drug development expertise to advance therapies for significantly unmet medical needs.
Don't miss Convergen's next move
Get an email the moment Convergen raises, hires an exec, or expands, usually minutes after it happens.
Suzhou CityBiotechnologyHealth CareMedical